IL24 and neoplasm: Results showed that tumor growth in VG9-IL-24-treated mice was notably slower compared with VG9-EGFP or control group and the survival rate of VG9-IL-24 group was 60%, which was similar with the other recombinant vaccinia virus carrying IL-12 in previous study 6.